QM · rank #7 · 2026-09-10
LQDA
NASDAQ · $6.14B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +315.33% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +131.8% |
| Profit margin Net profit margin, trailing 12 months. | +30.7% |
| Market cap (USD) Size filter: > $500M required. | $6.14B |
| Anchor (recent) Close on 2026-08-11 | $88.05 |
| Anchor (far) Close on 2025-08-11 | $21.20 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies is a rare cardiopulmonary specialty pharma company commercializing YUTREPIA, an inhaled dry-powder treprostinil for PAH and PH-ILD, with no other meaningful revenue streams.
Rationale
The quality_momentum signal is well-grounded: YUTREPIA net sales grew 31% sequentially to $170.4M in Q2 2026, four consecutive quarters of profitability, a 30%+ profit margin, and ROE above 1.3x collectively confirm genuine earnings momentum rather than sentiment-only rotation.
Material risks
- 1Single-product concentration in YUTREPIA means any safety signal, label restriction, or generic/biosimilar treprostinil entry would collapse the revenue base with no offset, directly breaking the quality leg of the thesis.
- 2Payer pushback or formulary exclusion on a high-cost specialty therapy could compress net pricing and stall the sequential growth trajectory that underpins the momentum signal.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.